Key Details
Last Dividend
$7.20Annual ROE
-12.05%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 09, 2023Recent annual earnings:
Feb 28, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
Mar 06, 2023Next split:
N/ARecent split:
Mar 08, 2023Analyst ratings
Recent major analysts updates
16 Aug '21 HC Wainwright & Co.
Neutral17 Feb '21 HC Wainwright & Co.
Buy17 Feb '21 Canaccord Genuity
Buy11 June '19 HC Wainwright & Co.
Buy11 June '19 H.C. Wainwright
Buy23 July '18 Jefferies
BuyScreeners with SESN included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Sesen Bio?
- What is the ticker symbol for Sesen Bio?
- Does Sesen Bio pay dividends?
- What sector is Sesen Bio in?
- What industry is Sesen Bio in?
- What country is Sesen Bio based in?
- When did Sesen Bio go public?
- Is Sesen Bio in the S&P 500?
- Is Sesen Bio in the NASDAQ 100?
- Is Sesen Bio in the Dow Jones?
- When was Sesen Bio's last earnings report?
- When does Sesen Bio report earnings?
- Should I buy Sesen Bio stock now?
What is the primary business of Sesen Bio?
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
What is the ticker symbol for Sesen Bio?
The ticker symbol for Sesen Bio is NASDAQ:SESN
Does Sesen Bio pay dividends?
No, Sesen Bio does not pay dividends
What sector is Sesen Bio in?
Sesen Bio is in the Healthcare sector
What industry is Sesen Bio in?
Sesen Bio is in the Biotechnology industry
What country is Sesen Bio based in?
Sesen Bio is headquartered in United States
When did Sesen Bio go public?
Sesen Bio's initial public offering (IPO) was on 06 February 2014
Is Sesen Bio in the S&P 500?
No, Sesen Bio is not included in the S&P 500 index
Is Sesen Bio in the NASDAQ 100?
No, Sesen Bio is not included in the NASDAQ 100 index
Is Sesen Bio in the Dow Jones?
No, Sesen Bio is not included in the Dow Jones index
When was Sesen Bio's last earnings report?
Sesen Bio's most recent earnings report was on 9 May 2023
When does Sesen Bio report earnings?
The date for Sesen Bio's next earnings report has not been announced yet
Should I buy Sesen Bio stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions